EUSA Pharma acquires global rights to oncology support drug

pharmafile | April 12, 2016 | News story | Manufacturing and Production, Research and Development, Sales and Marketing |  Eusa Pharma, acroral, acroral tab, global rights, oncology 

EUSA Pharma has announced the acquisition of global rights to oncology support care product, Arcoral Tab, from Arcoral Pharma.

Arcoral Tab is a topical oral agent used in the treatment of conditions resulting in reduced salivary flow such as xerostomia and hyposalivation caused by radiotherapy, mucositis, surgery, Sjörgens syndrome or obstruction in the salivary glands. The drug is characterised by high concentrations of calcium and phosphate ions, and lubricates the mucosa of the mouth, tongue and oropharynx and helps maintain the integrity of the oral cavity through its mineralising potential.

The English-based company will rebrand the drug under its existing Caphosol product. Arcoral has the same active ingredients as Caphosol but comes in a more convenient formulation of an effervescent tablet which produces mouth rinse.

EUSA intends to market the drug across Europe, and will submit the product for approval in the US.

Lee Morley, chief executive officer at EUSA Pharma, says: “We are delighted to acquire the global rights to Arcoral Tab, which is an ideal strategic fit with our portfolio of speciality medicines, and our focus on oncology and oncology supportive care. This next generation formulation represents an important advance on our existing Caphosol product, and demonstrates EUSA’s commitment to introducing next generation treatments to help specialists meet their patients’ needs.”

Sean Murray